The FDA approved Eli Lilly's new migraine drug, Reyvow, making it the drugmaker's second migraine drug approval this year.
Reyvow is a complementary therapy to Eli Lilly's other migraine drug, Emgality, making Eli Lilly the franchise leader in migraine treatments, according to Endpoints News.
The drug was approved Oct. 11 after two randomized, double-blind placebo-controlled trials with 3,177 adult patients with histories of migraines. The drug was shown to relieve migraine symptoms within two hours.
The most common side effects from Reyvow were dizziness, fatigue, a burning or prickling sensation in the skin, known as paresthesia, and sedation.
The approval of two migraine medications in the last year is rare for Eli Lilly's historically slow-moving research and development group, according to Endpoints News.
Read the full article here.